ESMO Media Releases

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer, EGFR status may help select patients who will benefit most

Promising new data from trials aimed at delaying resistance to BRAF inhibitors

Landmark global survey reveals major shortcomings in many countries around the world

811 people surveyed by Prof Tejpar and colleagues

Where are the most promising developments from first-in-human studies?

Head-to-head study compares of crizotinib with standard chemotherapy in this patient group

New trial results on pazopanib and temsirolimus have important implications for patients

Debate at ESMO 2012 Congress focuses on whether there is enough evidence to start using aspirin to reduce the risk of colorectal cancer

Study opens a new door to more personalised treatment of advanced breast cancer

New findings highlight the challenges of managing blood clotting in cancer patients